Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 12Biopsy 10Specimen Handling 9Whole-Body Irradiation 7Magnetic Resonance Spectroscopy 7pembrolizumab 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Etoposide 6fludarabine 5duvelisib 5Brentuximab Vedotin 5ruxolitinib 4fludarabine phosphate 4Vincristine 4Prednisone 4Doxorubicin 4Cytarabine 410-propargyl-10-deazaaminopterin 4romidepsin 3X-Rays 3Mycophenolic Acid 3Immunoglobulin G 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Disulfides 3Carmustine 3venetoclax 2tazemetostat 2sodium-iodide symporter 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × EPOCH protocol × 1 year × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡